To evaluate the clinical efficacy and safety of diode laser enucleation of the prostate (DiLEP) versus bipolar plasma kinetic enucleation of the prostate (PKEP) in the management of benign prostatic hyperplasia (BPH). A systematic literature search was undertaken using PubMed, Embase, Web of Science, Cochrane Library, and CKNI databases to identify eligible studies published before April 2019. The quality of evidence and methodology was assessed. Primary outcomes were clinical and demographic characteristics and postoperative efficacy including maximum flow rate (Qmax), postvoid residual (PVR), quality of life (QoL), and International Prostate Symptom Score (IPSS); secondary outcomes were intraoperative variables and major complications. Meta-analyses of extracted data were performed with the RevMan version 5.2. The overall effects were determined by the Z-test, and a p value less than 0.05 was considered with significant difference. A fixed- or random-effect model was chosen to fit the pooled heterogeneity (determined by Chi-squared test and I). As qualified trials were few, subgroup analyses were not performed. Four randomized controlled trials (RCTs) involving 451 patients were enrolled in our meta-analysis. In the included trials, all the diode (wavelength at 980 nm and 1470 nm) lasers applied output at continuous wave mode; the energy settings ranged from 120 to 160 W for enucleation and 30 to 60 W for coagulation. DiLEP provided less perioperative hemoglobin decrease (MD = - 3.22; 95% CI (- 5.15, - 1.29); p = 0.001; I = 65%), less postoperative catheterization time (MD = - 17.82; 95% CI (- 32.74, - 2.90); p = 0.02; I = 96%), less postoperative irrigation time (MD = - 7.15; 95% CI (- 13.67, - 0.62); p = 0.03; I = 98%), and lower incidence of urinary irritative symptoms (OR = 0.31; 95% CI (0.14, 0.67); p = 0.003; I = 0%) compared with PKEP. During the 1, 3, 6, and 12-month postoperative follow-up, no statistically significant difference was found in Qmax, IPSS, QoL, and PVR between the procedures. As regards other perioperative and postoperative parameters and major complications, we found no significant difference. Both DiLEP and PKEP are safe and efficient methods for the treatment of BPH. However, DiLEP showed less perioperative hemoglobin decrease, less postoperative catheterization time, less postoperative irrigation time, and lower rates of postoperative irritative symptoms compared with the PKEP group.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10103-020-02949-9 | DOI Listing |
Low Urin Tract Symptoms
January 2025
Farwaniya Hospital, Farwaniya, Kuwait.
Objectives: During holmium laser enucleation of the prostate (HOLEP), blunt dissection (BD) by pushing the tip of the scope may exert mechanical force on the sphincter that could be avoided by adopting laser dissection (LD). This study evaluates the continence recovery in consecutive patients who underwent BD and LD.
Methods: A prospective cohort of patients who underwent LD was compared with a retrospective control that underwent BD.
Arab J Urol
September 2024
Urology Department, Misr University for Science and Technology, 6th of October City, Egypt.
Background And Purpose: Though TURP remains the primary treatment for BPH, advancements in energy and technology have introduced innovative transurethral surgical options. In this study, we assessed and compared the effectiveness and safety of using thulium laser and bipolar for endoscopic enucleation of prostate exceeding 80 g.
Patients And Methods: Between January 2022 and July 2023, this study enrolled patients with LUTS due to BPH and a prostate size of ≥80 g.
BJUI Compass
December 2024
Miller School of Medicine Desai Sethi Urology Institute, University of Miami Miami Florida USA.
Introduction: Water Jet Ablation Therapy (WJAT) and Holmium Laser Enucleation of the Prostate (HoLEP) represent two common surgical treatments for Benign Prostatic Hyperplasia (BPH). Despite their increasing use, there is no study between these two methods. We aim to evaluate their efficacy and safety through a network meta-analysis (NMA), providing critical insights for clinical decision-making in the management of moderate to severe lower urinary tract symptoms (LUTS) due to BPH.
View Article and Find Full Text PDFAcad Radiol
December 2024
Department of Interventional Radiology, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Gulou District, Nanjing 210029, China (Z.-W.X., C.-G.Z., W.T., H.-B.S., S.L.). Electronic address:
Rationale And Objectives: To compare the long-term efficacy of prostatic artery embolization (PAE) with PAE followed by holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH) in patients with large prostatic volume (PV>80 cm), and to identify the appropriate population for PAE+HoLEP.
Methods: From March 2015 to December 2023, 208 consecutive BPH patients were enrolled into two groups: PAE monotherapy (Group A, n=168) and PAE followed by HoLEP (Group B, n=40). Differences in clinical and functional parameters between baseline and each follow-up point were compared.
World J Urol
December 2024
Desai Sethi Urology Institute, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA.
Purpose: In patients with prostate cancer (PCa), focal therapy with High-Intensity Focused Ultrasound (HIFU) combined with benign prostatic hyperplasia (BPH) surgery has been used to improve immediate post-operative voiding symptoms. Our study aimed to evaluate the functional outcomes of patients undergoing simultaneous holmium laser enucleation of the prostate (HoLEP) + HIFU and compare them to those who underwent HoLEP for bladder outlet obstruction secondary to BPH.
Methods: We performed retrospective review of patients who underwent HoLEP + HIFU or HoLEP between June 2017 and May 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!